Corbus Pharmaceuticals Reports FDA Clearance to Initiate TEMPO-1 Trial of CRB-701 in OPSCC

Shots: The US FDA has granted clearance to initiate a registrational study (TEMPO-1) of CRB-701, a Nectin-4-targeted ADC, in 2L oropharyngeal squamous cell carcinoma (OPSCC), with enrolment beginning in Sep 2026 Trial (n=250) will evaluate the efficacy & safety of CRB-701 vs investigator’s choice of capecitabine, cetuximab or docetaxel, assessing ORR as the 1EP to…

ByRidhi RastogiJuly 29, 2026

NEWS

AbbVie Reports the US FDA’s NDA submission of Tavapadon to Treat Parkinson’s Disease

Shots: The US FDA has received an NDA for tavapadon (QD, PO) for Parkinson’s disease (PD), supported by P-III (TEMPO-1 & 2) trials in early PD & P-III (TEMPO-3) evaluating adjunctive use with levodopa in pts with motor fluctuations, plus interim data from P-III (TEMPO-4) open label study TEMPO-1 (n=529) & TEMPO-2 (n=304) evaluated fixed…

ByRidhi RastogiSeptember 29, 2025

Corbus Pharmaceuticals Reports FDA Clearance to Initiate TEMPO-1 Trial of CRB-701 in OPSCC

AbbVie Reports the US FDA’s NDA submission of Tavapadon to Treat Parkinson’s Disease

Contact US

FOLLOW US